Trial Profile
A Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity and Immune Persistence of COVID-19 mRNA Vaccine in Healthy People Aged 18 Years and Above.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Coronavirus vaccine-Stemirna Therapeutics/Tongji University (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Stemirna Therapeutics
- 25 Dec 2022 Status changed from active, no longer recruiting to completed.
- 06 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2022 Planned primary completion date changed from 10 Feb 2022 to 10 Apr 2022.